Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 8:56 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 92 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Naltrexone Clear all
Completed Phase 2 Interventional

Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence

NCT00332228
View directory record Official record
Conditions
Opiate Dependence
Interventions
depot naltrexone, Compliance enhancement (CE), BNT
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections

NCT04828694
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
BICX104, Vivitrol
Drug
Lead sponsor
BioCorRx Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Nov 2, 2026, 8:56 AM EST
Recruiting Phase 3 Interventional

Emergency Department-Initiated Medications for Alcohol Use Disorder

NCT05827159
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone Pill, Naltrexone Injection, Brief Negotiation Interview, Gabapentin Pill
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Long-acting Naltrexone for Pre-release Prisoners

NCT02867124
View directory record Official record
Conditions
Opiate Addiction
Interventions
XR-NTX, place of residence, opioid treatment program
Drug · Other
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Nov 2, 2026, 8:56 AM EST
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol

NCT03113409
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine, Naltrexone, Vivitrol
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 2 Interventional Results available

Employment-Based Depot Naltrexone Clinical Trial

NCT00684788
View directory record Official record
Conditions
Opiate Dependence
Interventions
employment-based reinforcement
Combination Product
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 1 Interventional

Improved Strategies for Outpatient Opioid Detoxification

NCT01377610
View directory record Official record
Conditions
Opioid Dependence
Interventions
oral naltrexone, Buprenorphine, Vivitrol
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Nov 2, 2026, 8:56 AM EST
Enrolling by invitation No phase listed Observational

A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy

NCT05503927
View directory record Official record
Conditions
Pregnancy, Obesity, Overweight
Interventions
No Intervention
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
2,701 participants
Timeline
2020 – 2027
U.S. locations
2
States / cities
Ann Arbor, Michigan • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 2, 2026, 8:56 AM EST
Not yet recruiting Phase 1Phase 2 Interventional

Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder

NCT07871877
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
Interventions
Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo, Matching Intramuscular Placebo, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform, Standardized Psychological Preparation, Integration and Recovery Support, Garmin-Enabled Longitudinal Wellness Monitoring
Drug · Device · Behavioral + 1 more
Lead sponsor
Clive Michelsen
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Basalt, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 4 Interventional Results available

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

NCT03799198
View directory record Official record
Conditions
Obesity
Interventions
Weight Management Program (WMP), Medication for chronic weight management (Rx)
Other · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Nov 2, 2026, 8:56 AM EST
Completed Not applicable Interventional Results available

Alcohol Pharmacotherapy for HIV+ Prisoners

NCT01077310
View directory record Official record
Conditions
Alcohol Dependence, Problem Drinking, Hazardous Drinking, Human Immunodeficiency Virus, AIDS
Interventions
Vivitrol- Intramuscular naltrexone (depot-formulation), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 1Phase 2 Interventional Results available

Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

NCT02461927
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Ketamine + Naltrexone, Ketamine + Placebo, Placebo (psychoactive placebo midazolam) + Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 2Phase 3 Interventional Results available

Improving Treatment Outcomes for Prescription Opioid Dependence

NCT02543944
View directory record Official record
Conditions
Drug Dependence
Interventions
Gabapentin, Buprenorphine, Clonidine, Naltrexone (oral), Naltrexone (depot), Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 2 Interventional Results available

Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence

NCT02437344
View directory record Official record
Conditions
Opioid Dependence
Interventions
CI-581aa, Naltrexone titration and XR-NTX initiation
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence

NCT02088177
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Long-acting injectable naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Nov 2, 2026, 8:56 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Depot Naltrexone Treatment of Opioid Dependent Parolees

NCT00756990
View directory record Official record
Conditions
Opioid Dependence
Interventions
Depot Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 4 Interventional

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

NCT04276259
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
Buprenorphine, Naltrexone, Oral Placebo, IM Placebo, Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.
Drug · Device
Lead sponsor
Marta Peciña, MD PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 4 Interventional

Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)

NCT00453804
View directory record Official record
Conditions
Bipolar Disorders, Schizophrenia, Schizoaffective Disorders, Alcohol Dependence
Interventions
injectable naltrexone, oral naltrexone
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2008 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 2 Interventional Results available

CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery

NCT01587196
View directory record Official record
Conditions
Prescription Opiate/Medication Dependence
Interventions
Vivitrol
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Nov 2, 2026, 8:56 AM EST
Terminated Phase 1 Interventional

Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia

NCT06374290
View directory record Official record
Conditions
Smoking Cessation
Interventions
Naltrexone (Vivitrol), Bupropion
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 3 Interventional Results available

Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study

NCT01908062
View directory record Official record
Conditions
Opioid Use Disorder, Alcohol Use Disorder
Interventions
Extended Release Naltrexone, Treatment As usual
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Nov 2, 2026, 8:56 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol

NCT07269873
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
BICX104 naltrexone implantable pellet, Bupropion 150 mg XL, Naltrexone (depot)
Drug
Lead sponsor
BioCorRx Pharmaceuticals Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 2, 2026, 8:56 AM EST
Completed Phase 4 Interventional Results available

Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care

NCT01893827
View directory record Official record
Conditions
Alcohol Dependence
Interventions
XR-NTX (Extended-Release Naltrexone), Oral Naltrexone (O-NTX)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Nov 2, 2026, 8:56 AM EST
Terminated Phase 2 Interventional Results available

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

NCT04480554
View directory record Official record
Conditions
Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
Interventions
Methadone, Buprenorphine/naloxone, XR-Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 2, 2026, 8:56 AM EST